JNJ-64530440（JNJ-0440），一种新型乙型肝炎病毒（HBV）衣壳组

StephenW

The Liver Meeting San Francisco November 2018 Back

Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV)             Reported by Jules Levin AASLD 2018 Nov 9-13 SF Dr. Thomas Kakuda1, Dr. Jeysen Yogaratnam1, Dr. Edward J. Gane2, Dr. Christian Schwabe2, Christopher Westland1, Jennifer Vuong1, Willem Talloen3, Oliver Lenz3, John Fry1, Ms. Sushmita Chanda1 and Dr. Pieter Van Remoortere4, (1)Alios Biopharma Inc., Part of the Janssen Pharmaceutical Companies, South San Francisco, CA, USA, (2)New Zealand Liver Transplant Unit, University of Auckland, Auckland, New Zealand, (3)Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium, (4)Janssen Research & Development, Janssen Pharmaceuticals, Titusville, New Jersey, USA

齐欢畅